Systemic corticosteroids (CS) are often used in treatment of @entity30 and are usually considered the main cause of @entity170 in @entity1 with @entity30 . The aim of this paper was to assess the influence of CS on development of @entity170 in @entity30 . In this study @entity79 ( @entity79 ) was analyzed in 43 @entity1 with @entity30 . Most of the examined @entity1 (72.1%) used CS for more than 3 months. @entity170 was diagnosed in 30.2% of @entity1 , and @entity2331 in 44.2% of @entity1 . There were no statistically significant difference in @entity79 among @entity1 who were on CS and the ones who were not. In the group of newly diagnosed @entity1 60% had reduced bone density, opposing 61.6% of @entity1 with previously diagnosed disease. There was no statistically significant difference among those two groups of @entity1 . Risk factor such as corticosteroid therapy is not independent risk factor for reduced @entity79 . Newly diagnosed @entity1 have high prevalence of reduced @entity79 and they were not on CS therapy, which suggest that possible inflammatory nature of the disease is a possible risk factor for reduced @entity79 in @entity30 .

[The influence of corticosteroid therapy on development of XXXX in @entity30 ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['BMD', 'bone mass density'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']
